Gannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic Steatohepatitis

--Up to 68.2% mean relative reduction in liver fat content from baseline in biopsy-confirmed non-alcoholic steatohepatitis patients receiving 12-week treatment of ASC41 tablet
--At Week 12, up to...

Related Keywords

China ,Hong Kong ,Shanghai ,Jinzij Wu , ,Hong Kong Stock Exchange ,Ascletis Pharma Inc ,Prnewswire Gannex Pharma Co Ltd ,Ascletis Pharma ,Liver Fat Content ,Liver Inflammatory Biomarkers ,Markets ,